非肌层浸润性膀胱癌早期复发与后续复发及进展风险
基于丹麦全国登记数据,纳入2009至2020年诊断且至少复发一次的非肌层浸润性膀胱癌患者6886例,按首次复发时间≤12个月(早期)或>12个月(晚期)分组。早期复发者1年后续复发累积发生率为47%,晚期为26%;1年进展发生率分别为10%和4.0%。调整后早期复发与后续复发(HR 1.73)及进展(HR 1.75)风险显著升高相关。
要点
- 首次复发≤12个月者1年后续复发风险47%,显著高于晚期复发者的26%。
- 早期复发者1年进展发生率为10%,晚期复发者为4.0%。
- 首次复发时间可作为预后标志,或影响随访策略。
核心结论
- 原发非肌层浸润性膀胱癌诊断后早期复发与后续复发和进展风险显著升高相关。
- 首次复发的时间可能作为临床相关预后标志,并可能影响未来随访策略。
研究设计与样本
- 基于丹麦全国健康登记数据的回顾性队列研究。
- 纳入2009至2020年诊断且至少经历一次复发的非肌层浸润性膀胱癌患者6886例。
- 按首次复发时间分组:早期(≤12个月)3898例,晚期(>12个月)2988例。
- 采用Cox比例风险模型估计调整风险比,调整年龄、性别、原发T分期和分级;并采用Prentice-Williams-Peterson总时间模型。
主要发现
- 早期复发组1年后续复发累积发生率为47%(95% CI 45-49),晚期复发组为26%(95% CI 24-28)。
- 早期复发组1年进展累积发生率为10%(95% CI 9.5-11),晚期复发组为4.0%(95% CI 3.4-4.8)。
- 后续复发的调整HR在Cox模型中为1.73(95% CI 1.63-1.85;P < .001),在PWP模型中为1.19(95% CI 1.12-1.25;P < .001)。
- 进展的调整HR为1.75(95% CI 1.55-1.98;P < .001)。
临床怎么用
- 对于非肌层浸润性膀胱癌首次复发≤12个月的患者,应考虑更密切的随访以监测后续复发和进展。
- 首次复发时间可作为风险分层工具,辅助个体化随访策略制定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate how the timing of the first non-muscle invasive bladder cancer (NMIBC) recurrence influences the risk of subsequent recurrences and progression. Furthermore, to examine the relationship between multiple recurrences in NMIBC. METHODS: Using nationwide Danish health registers, we identified NMIBC patients diagnosed between 2009 and 2020 who experienced at least one recurrence. Patients were categorized by timing of first recurrence: early (≤12 months from primary diagnosis) or late (>12 months). We estimated cumulative incidences of subsequent recurrences and progression. Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) for early vs late recurrence, adjusting for age, sex, primary T-stage, and grade. The Prentice-Williams-Peterson (PWP) Total Time model estimated the hazard of subsequent recurrences when accounting for previous recurrences. RESULTS: Among 6886 patients with recurrence, 3898 were early and 2988 late. The 1-year cumulative incidence of subsequent recurrence was 47% (95% CI 45-49) for early vs 26% (95% CI 24-28) for late recurrence. Corresponding 1-year progression incidences were 10% (95% CI 9.5-11) and 4.0% (95% CI 3.4-4.8). Adjusted HRs for subsequent recurrence were 1.73 (95% CI 1.63-1.85; P < .001) in Cox models and 1.19 (95% CI 1.12-1.25; P < .001) in the PWP model. For progression, the adjusted HR was 1.75 (95% CI 1.55-1.98; P < .001). CONCLUSION: Early recurrence after primary NMIBC diagnosis was associated with significantly higher risks of subsequent recurrence and progression. Timing of the first recurrence may serve as a clinically relevant prognostic marker and could influence future follow-up strategies.
引用
- Hjort PB, Jensen JB, Ernst A, et al. Risk of Subsequent Recurrences and Progression in Non-muscle Invasive Bladder Cancer Patients With Early Recurrence. Urology. 2026. PMID: 42731680. doi:10.1016/j.urology.2026.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。